Tender Details
Ref No 19397525
Document

Tender Notice

Bidding

Not specified

Short Description

75.2025 Placebo Production Service For The Purposes Of Clinical Examination And Product Management Service For The Needs Of The Project A Randomized, Double-Blind, Three Parall-Group, Placebo Controlled Superiority Trial Assessing The Effect Of Intravenous Versus Oral Iron Supplementation On Physical Performance In Iron Deficent Frail Eldividules With Cardiovascular Disca
Deadline *
Date 09 Sep 2025
* The estimated cost, values & dates are indicative only. Please read tender document for accurate information.
Client Address
Location Poland
More Information
Know More

FREE Trial Plan For All New Users!

Start your Business.

Similar Tenders

  • Ref No: 3695292
  • Location: United States

Services For Dhs Clients Under The Limited Supports Waiver

  • Deadline: 01 Dec 2025
  • Ref No: 5306291
  • Location: Germany

Open House Drug Discount Agreements Rivaroxaban Film Coated Tablets Except With A Strength Of 2 5 Mg Atc B01Af01

  • Deadline: 05 Apr 2026
  • Ref No: 5304038
  • Location: Germany

Open House Drug Discount Contracts In Accordance With Section 130A Paragraph 8C Sgb V Pemetrexed Atc L01Ba04

  • Deadline: 16 Apr 2026
  • Ref No: 5310172
  • Location: Germany

Open House Drug Discount Contracts In Accordance With Section 130A Paragraph 8C Sgb V Bortezomib Atc L01Xg01

  • Deadline: 16 Apr 2026
  • Ref No: 5396790
  • Location: Germany

Conclusion Of A Non Exclusive Discount Agreement According To Section 130A Paragraph 8 Sgb V For Medicinal Products Containing The Active Ingredient L

  • Deadline: 27 Apr 2026
  • Ref No: 4640403
  • Location: Germany

Conclusion Of Non Exclusive Discount Agreements In Accordance With Sections 130A Paragraph 8 130C Paragraph 1 Sgb V For Medicines With The Active Ingr

  • Deadline: 28 Feb 2026
  • Ref No: 4640423
  • Location: Germany

Conclusion Of Non Exclusive Discount Agreements In Accordance With Sections 130A Paragraph 8 130C Paragraph 1 Sgb V For Medicines With The Active Ingr

  • Deadline: 28 Feb 2026
  • Ref No: 4640900
  • Location: Germany

Conclusion Of Non Exclusive Discount Agreements In Accordance With Sections 130A Paragraph 8 130C Paragraph 1 Sgb V For Medicines With The Active Ingr

  • Deadline: 28 Feb 2026
  • Ref No: 4640967
  • Location: Germany

Conclusion Of Non Exclusive Discount Agreements In Accordance With Sections 130A Paragraph 8 130C Paragraph 1 Sgb V For Medicines With The Active Ingr

  • Deadline: 28 Feb 2026
  • Ref No: 4641684
  • Location: Germany

Conclusion Of Non Exclusive Discount Agreements In Accordance With Sections 130A Paragraph 8 130C Paragraph 1 Sgb V For Medicines With The Active Ingr

  • Deadline: 28 Feb 2026
  • Ref No: 4642060
  • Location: Germany

Conclusion Of Non Exclusive Discount Agreements In Accordance With Sections 130A Paragraph 8 130C Paragraph 1 Sgb V For Drugs With The Active Ingredie

  • Deadline: 28 Feb 2026
  • Ref No: 4643255
  • Location: Germany

Conclusion Of Non Exclusive Discount Agreements In Accordance With Sections 130A Paragraph 8 130C Paragraph 1 Sgb V For Medicines With The Active Ingr

  • Deadline: 28 Feb 2026
  • Ref No: 4643536
  • Location: Germany

Conclusion Of Non Exclusive Discount Agreements In Accordance With Sections 130A Paragraph 8 130C Paragraph 1 Sgb V For Medicines With The Active Ingr

  • Deadline: 28 Feb 2026
  • Ref No: 4646012
  • Location: Germany

Conclusion Of Non Exclusive Discount Agreements In Accordance With Sections 130A Paragraph 8 130C Paragraph 1 Sgb V For Drugs With The Active Ingredie

  • Deadline: 28 Feb 2026
  • Ref No: 4644671
  • Location: Germany

Conclusion Of Non Exclusive Discount Agreements In Accordance With Sections 130A Paragraph 8 130C Paragraph 1 Sgb V For Drugs With The Active Ingredie

  • Deadline: 28 Feb 2026